Försök har visat att den kan återställa funktionen hos p53 vid olika typer av mutationer. Det tycks vara den hittills mest lovande substansen för att reaktivera p53, säger Galina Selivanova. De första kliniska försöken. Sommaren 2009 startade de första kliniska försöken med PRIMA-1 p53 Gene Mutations . A mutation in the p53 gene (located on chromosome 17) is the most common mutation found in cancer cells and is present in over 50% of cancers. Talking about gene mutations and cancer, especially with tumor suppressor genes is confusing, because there are two primary types: germline and somatic mutation i TP53-genen Introduktion Dessa riktlinjer avseende påvisad handläggning vidmedfödd mutation i TP53-genen (tumor protein p53) har framtagits inom ramen för SWEA-studien, där familjer som enligt klinisk rutin uppfyller kriterier för analys av BRCA1/2 också erbjuds testning av ett flertal andra gener, inklusive
Muterad p53 - cancercellens beskyddare. Om p53 skyddar friska celler från förvandlas till cancerceller, är muterad p53 cancercellernas beskyddare. Nästan hälften av alla cancrar har en mutation i p53, vilket gör den till den mest muterade genen i cancer The TP53 gene is frequently mutated in human cancer. Research has focused predominantly on six major hotspot codons, which account for only ∼30% of cancer-associated p53 mutations. To comprehensively characterize the consequences of the p53 mutation spectrum, we created a synthetically designed li
p53 mutations in 10,000 cancer patients shed new light on gene's function Date: July 30, 2019 Mutation of this gene eliminates a key cellular fail-safe mechanism and is a step leading to cancer TP53 (p53) is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% of all invasive tumours. However, in some of the most difficult-to-treat cancers such as high-grade serous ovarian cancers, triple-negative breast cancers, oesophageal cancers, small-cell lung cancers and squamous cell lung cancers, p53 is mutated in at least 80% of samples Mutations are among most commonly detected genetic abnormalities in human neoplasia; however, presence of p53 mutation is usually not, by itself, specific enough for a diagnosis for malignancy, and its absence does not rule out malignancy Li-Fraumeni syndrome: germline heterozygous mutation in p53
Although the mutation status of p53 is not uniformly associated with prognosis, 65 out of 93 tumor cohorts consisting of 16 different tumor types showed a tight association between mutant p53 and poor prognosis, which argues strongly for the importance of p53 mutation status in cancer management. 22 Thus, the question that perhaps needs to be addressed is why, in some tumor types, p53 mutation. Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice. HUMAN MUTATION 2014 TP53 SPECIAL ISSUE Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T (2014)
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429. Citation on PubMe point mutation in p53 structure, which diminishes p53:G-actin complexation results in mutant p53 altered subcellular localization. both the p53-Puma/Noxa/Bax pathway and the cell cycle arrest-associated p53-p21 pathway were involved in the AZT-induced cell cycle arrest (p53-p21) and DNA double-strand breaks (gamma-H2AX), while euploid cells were more sensitive to AZT-induced apoptosis (p53. Keywords. gain of function; mutant p53; oncogenic; p53; transcriptome; tumor suppression; The TP53 gene, which resides on chromosome 17p13.1 and encodes the p53 protein, is the most frequent target for mutation in human cancer, with greater than half of all tumors exhibiting mutation at this locus (Vogelstein et al. 2000; Petitjean et al. 2007b) Results: p53 mutation, identified in 64/246 (26%) of cancers, was most common in 10 out of 17 (58.8%) of the lowest (10th) deprivation decile. Those patients with p53 mutation in the 10th decile had a significantly worse disease-free survival of only 20% at 5 years (Kaplan-Meier logrank χ 2 =6.050, P=0.014) and worse overall survival of 24% at 5 years (Kaplan-Meier logrank χ 2 =6.791, P. Demnach ist p53 wie eine Art Bremse, die nötig ist, um Zellen vom unkontrollierten Wachstum und weiterer Schädigung abzuhalten, und deren Mutation zu verstärkter Zellteilung führt. Eine andere Funktion von p53 ist, dass es offensichtlich das menschliche Schwangerschaftshormon hCG steuert, wie Wissenschaftler der Universität Leipzig nachweisen konnten
P53 mutation and survival. In general, among nonmutants, 22 of 49 patients died within 1 to 68 months (median, 13), whereas 14 of 17 patients with a mutation died within 1 to 88 months (median, 12; P < .05). In 15 patients, a mutation in P53 was identified at diagnosis; data on survival were available from 13 of these patients (Table 1) The mutation database. The UMD_TP53 database is the only mutation database that provides a curated set of TP53 mutations . Each publication is associated with a confidence index that allows the user to choose to work with a specific dataset (see the curation page and the read me file for more info). Novelties in the 2017 release of the databas Mutation in the P53 Gene. P53 gene mutation have several different effects on the activity of the gene, depending on the location of the alteration. Mutations can occur in regulatory regions also called promoter, that basically control how often, and when, the gene is transcribed. Here mutation can result in a decrease or absence of p53 in the. p53은 암 억제 단백질로 인간은 TP53 유전자로 암호화 되어 있다. P53은 다세포 생물의 세포 주기에서 암 억제자로서 암을 예방하기에 중요하다. 게놈의 돌연변이를 예방하여 게놈의 안정성을 보존하는 역할을 하기에 p53은 게놈의 수호자라고 서술된다.. p53의 이름은 분자량에서 온 것이다
This syndrome results normally from the inheritance of a mutant p53 gene, but analysis of an affected family that carries a wild-type p53 gene revealed a germ-line mutation in Chk2. While Chk2 is required to activate p53 in response to ionising radiation, Hirao et al.  found that Chk2 is dispensable for the p53 response in the presence of UV-induced damage However, p53 mutation status was not associated with worse patient outcome in patients with stage II or IIIA NSCLC (P = .26 and P = .42, respectively). Multiple regression analysis was performed using a Cox proportional hazards model to determine whether p53 gene mutations independently predicted survival in patients with operable NSCLC (Table 4) IARC TP53 Database: knowledgebase and statistical tools for the analysis of TP53 gene mutations in human cancer The U.S. Food and Drug Administration (FDA) has granted fast track status to PC14586, PMV Pharmaceuticals' lead therapeutic candidate for the treatment of patients with locally advanced or metastatic solid tumors, including breast cancer, who have a specific mutation in the gene that encodes the tumor suppressor protein p53.A fast track designation facilitates the development of potential. p53 mutation spectrum from the TCGA lung squamous and lung adenocarcinoma datasets. A graphical representation is shown of the percent with p53 mutations (colored) versus wild-type p53 (gray). The mutations within a 5-residue stretch are grouped and colored to represent one of four hotspot regions, around amino acid 157.
p53 mutation remains the most common genetic change identified in human neoplasia. In breast cancer, p53 mutation is associated with more aggressive disease and worse overall survival. The frequency of mutation in p53 is, however, lower in breast cancer than in other solid tumours. Changes, both genetic and epigenetic, have been identified in regulators of p53 activity and in some downstream. The mutation causes an amino acid change from arginine to histidine at codon 337. With pH in the low to normal physiological range (up to 7.5), the mutant protein forms normal oligomers and retains its suppressor function. However, at a high physiological pH, p53 is unable to assemble into a tetramer Therefore, p53 IHC− and BRCA1 status are independent tumor characteristics that correlate positively with the likelihood of having a protein-truncating TP53 mutation. Conversely, p53 IHC+ tumors were significantly more likely to have a common TP53 hotspot mutation compared with p53 IHC− tumors (OR = 25.2; P = 0.000 The DNA-binding domain of the tumor suppressor p53 is inactivated by mutation in ≈50% of human cancers. We have solved high-resolution crystal structures of several oncogenic mutants to investigate the structural basis of inactivation and provide information for designing drugs that may rescue inactivated mutants. We found a variety of structural consequences upon mutation: ( i ) the removal. The p53 mutation was an independent prognostic factor. We also evaluated the importance of the p53 mutation in patients classified according to the international prognostic index
en mutation av p53-genen först får effekt efter en mutation av PTEN, som är en annan tumörsuppressorgen. Forskning tyder på att mutationer i p53-genen sker sent i cancerogenesen, vilket i sin tur tyder på att även andra gener och faktorer spelar in vid tumörbildning Optimized p53 IHC can approach 100% specificity for the presence of TP53 mutation and its high negative predictive value is clinically useful as it can exclude the possibility of a low‐grade serous tumour. 4.1% of HGSOC cases have detectable WT staining while harboring a TP53 LOF mutation, which limits sensitivity for binary prediction of mutation to 96%
The tumor suppressor gene TP53 is frequently mutated in human cancers. Abnormality of the TP53 gene is one of the most significant events in lung cancers and plays an important role in the tumorigenesis of lung epithelial cells. Human lung cancers are classified into two major types, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC) p53, also known as TP53 or tumor protein (EC :184.108.40.206) is a gene that codes for a protein that regulates the cell cycle and hence functions as a tumor suppression. It is very important for cells in multicellular organisms to suppress cancer. P53 has been described as the guardian of the genome, referring to its role in conserving stability by preventing genome mutation (Strachan and Read. P53 tumor supressor Animation - This lecture video explains about the role of p53 in cell cycle regulation and the onset of cancer. P53 gene encodes in tumou.. mutation in TP53 may cause, many p53 mutants are able to actively promote tumor development by several other means. In a heterozygous situation, where both wild-type (WT) and mutant alleles exist, mutant p53 can antagonize WT p53 tumor sup-pressor functions in a dominant negative (DN) manner. The inactivation of the W Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases
The tumor suppressor protein p53 is a multifunctional transcription factor involved in the control of cell cycle progression, DNA integrity, and cell survival. p53 is mutated in half of all tumors and has a wide spectrum of mutation types. p53 mutants show different degrees of dominance over coexpressed wild-type p53, and loss of the wild-type p53 allele has been observed frequently Breast CanCer p53 HotsPot Mutation Cell Panel Figure 1. Cell morphology of eight cell lines in the Breast Cancer p53 Hotspot Mutation Cell Panel. Two p53 wild-type breast cancer cell lines, MDA-MB-175-VII and MDA-MB-361, and six p53 hotspot mutation breast cancer cell lines, AU565, SK-BR-3, HCC70, BT-549, HCC38 and MDA The p53 Y220C mutation is associated with many cancers including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic and ovarian cancers. About PC14586 PC14586 is a first-in-class small molecule designed to structurally correct the p53 Y220C mutant protein by binding to part of the p53 Y220C mutation, which restores the normal p53 protein structure and tumor. Mutation in tumor suppressor gene leads to cancer - Duration: 7:06. Shomu's Biology 12,137 views. The regulation and activation of P53 functions protect from cancer - Duration: 48:52
The importance of cancer-cell-autonomous functions of the tumour suppressor p53 (encoded by TP53 ) has been established in many studies, but it is now clear that the p53 status of the cancer cell also has a profound impact on the immune response. Loss or mutation of p53 in cancers can affect the recruitment and activity of myeloid and T cells, allowing immune evasion and promoting cancer. Background Whether increased expression of the tumor suppressor protein p53 indicates a p53 gene mutation in hepatocellular carcinoma (HCC) remains unclear. We conducted a meta-analysis to determine whether p53 protein overexpression detected by immunohistochemistry (IHC) offers a diagnostic prediction for p53 gene mutations in HCC patients P53 mutation hinders cancer treatment response Date: January 25, 2013 Source: SingHealth Summary: Scientists have discovered the workings of the gene that has been hindering treatment response in. p53 mutation than those with lymphomas devoid of p53 mutation. Overall survival time was signiﬁcantly shorter (67 days versus 264 days, P = .004) in dogs with lymphoma with p53 mutation than those with lymphoma retaining wild-type p53
p53 is a tumor suppressor protein that regulates a complex network of signals that can trigger cell cycle arrest, senescence, and/or apoptosis. Learn about the role of p53 in cancer, p53 dysfunction, and p53 reactivation PRIMA, p53 reactivation and induction of massive apoptosis. sulted from a p53 mutation [5,6], which was later called gain of oncogenic function . By the early 1990s, data from the first p53 knockout mice provided inarguable evidence in support of the potent tumor suppressor action of wt p53 
The p53 protein, made by the TP53 gene, normally acts as the supervisor in the cell as the body tries to repair damaged DNA. Different mutations can determine how well or how poorly that supervisor is able to direct the response. The more defective the mutation, the greater the risk Altered p53 protein is prevalently associated with the pathologic class of triple-negative breast cancers and loss of p53 function has recently been linked to the induction of an epithelial-mesenchymal transition (EMT) and acquisition of stemness properties. We explored the association between TP53 mutational status and expression of some genes involved in the canonical TGF-<i>β</i. The most predominant mutation observed in the p53 gene is a cytosine (C) to thymine (T) mutation that occurs at CpG dinucleotides located at the mutational hotspots [26, 27]
Of note, the p53 Y220C mutation has been categorized as the 9 th most frequent p53 missense mutation found in cancer with ~ 100,000 new cancer cases per year worldwide . In these premises, we investigated the structural differences between the wild type and these mutant proteins and the ability of Wi-A and Wi-N to interact with wild type/mutant p53 structures Die Mutationen wirken sich höchst unterschiedlich auf die Eigenschaften von p53 aus: z.B. erhöhen sie seine Halbwertszeit, lösen einen Konformationswechsel aus, führen zur Anreicherung im Cytoplasma oder verhindern die Bindung an defekte DNA. Mutationen im p53-Gen können in der Keimbahn auftreten und vererbt werden suppressor p53 (encoded by TP53) has been established in many studies, but it is now clear that the p53 status of the cancer cell also has a profound impact on the immune response. Loss or mutation of p53 in cancers can affect the recruitment and activity of myeloid and T cells, allowing immune evasion and promoting cancer progression However, the association between p53 mutation and retrotransposon expression is more than simply a culling effect: indeed, p53 binding to target sites within LINE elements and other transposon sequences are associated with their downregulation (Chang et al., 2007. Chang N.T. Yang W.K. Huang H.C. Yeh K.W p53 A gene that codes for P21. A tumour suppressor gene, the absence or mutation of which can greatly increase the probability that cancer will develop. When DNA damage, as from anticancer drugs, occurs in normal cells the expression of p53 is increased
p53 Mutants Data Set Download: Data Folder, Data Set Description. Abstract: The goal is to model mutant p53 transcriptional activity (active vs inactive) based on data extracted from biophysical simulations It is the target of 90% of p53 mutations found in human cancers as a single mutation within this domain can cause a major conformational change. The oligomerization domain (325-356) consists of a β-strand, which interacts with another p53 monomer to form a dimer, followed by an α-helix which mediates the dimerization of two p53 dimers to form a tetramer in our lab we use HCT cell lines wild type and null for p53. But if you want cell lines with mutated p53 use MDA-MB231 cell lines which is a highly metastatic breast cancer cell line
p53 benævnes genomets vogter og kaldes også tumorprotein p53, cellulært tumorantigen p53, tumor suppressor p53, antigen NY-CO-13, phosphoprotein p53 eller transformation-relateret protein 53, TRP53. p53 er det vigtigste oncoprotein, idet mere end halvdelen af alle kræfttilfælde viser sig at skyldes en eller anden mutation i p53 p53 mutation is one of the major results of ultraviolet (UV) radiation. UV photoproducts of cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidone (6-4) photoproducts (64PPs) also play.
p53 (TP53, Tumor Protein p53) Gene Mutation Analysis Li-Fraumeni Syndrome Germline (heritable) mutations in the p53 gene1 predispose individuals to various tumors (early onset sarcomas and breast cancer, brain tumors, adrenal cortical carcinomas, and leukemias) associated with Li-Fraumeni syndrome 2,3 Effect of mutations on p53 expression and transcriptional activity. The expression levels of p53 target genes, p21 and MDM2, were evaluated in 3 ovarian cancer cell lines (IGROV-1 with WT p53, OVCAR-3 with exon 7 mutation in p53, and p53-null SK-OV-3), and 5 ovarian cancer cases (cases 16 and 17 with WT p53, case 9 with a DNA binding domain mutation and cases 11 and 15 with proline rich domain. Pedrote of the first author of the study. The research was conducted using a p53-specific mutation (M237I). This is important because the native protein (without mutation) and other mutations are. p53 mutation is the most common genetic abnormality found in human cancer.12 In cell lines, loss of p53 activity is usually linked with several specific landmarks such as defect in growth arrest or apoptosis after DNA damage and lack of induction of p53-regulated genes.13,14 The p53 status is also a key factor for the sensitivit
ABSTRACT. Background: Alteration(s) on P53 gene adversely affects their regulatory functions resulting to cancers. To our knowledge, no previous studies have analyzed mutation in codon 249 of P53 gene in hepatocellular carcinoma (HCC) patients in Kenyan population. In our study, we investigated for these mutations in HCC patients presenting with stage one cancer in the Kenyan population p53 es una proteína supresora de tumores.  En la especie humana, el gen p53 o TP53, también llamado el guardián del genoma, se encuentra en el brazo corto del cromosoma 17 (17p13) y codifica un factor de transcripción nuclear de 43.7 KDa.Su nombre hace referencia a su masa molecular aparente: corre como una proteína de 53 KDa en un SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel.
P53 immunohistochemistry has evolved into an accurate surrogate reflecting the underlying TP53 mutation status of a tumor, and has utility in the diagnostic workup of endometrial carcinomas. Recent work predominantly carried out in tubo-ovarian high-grade serous carcinoma has revealed 4 main patterns of p53 staining (normal/wild-type, complete absence, overexpression, and cytoplasmic); the. The tumor suppressor p53 is inactivated by mutation in about half of all tumors, making mutant p53 a prime target for cancer therapy. Most oncogenic p53 mutations are missense mutations mapping to its DNA-binding domain (DBD), yet the functional spectrum of these mutations is very diverse, depending on the distinct nature of each mutant protein The p53-R175H hotspot mutation occurs in ~4.5% of all cancers, and as such, is an attractive target for adoptive T cell immunotherapy. Normal tissue does not express the mutated p53 protein. Therefore, these TCRs are expected to specifically eliminate human cancer cells that express both the appropriate p53 mutant and HLA molecules upon adoptive transfer into patients
. Mutation analysis of p53 via exon sequencing is commonly used in clinical practice for assessment of p53 functionality in surgically removed tumours. Through a joint programme with Polenov Institute of Neurosurgery, St Petersburg, Russia, we identified a C to G nucleotide substitution at position 378 of the p53 open reading (378C>G mutation) in one DNA sample extracted from surgical material.
Frequent mutation at the p53 locus in P1 −/− /D −/− tumors. (a) Immunodetection of p53 in extracts from early-passage tumor cells (left and middle blot) or fresh tumor tissue (right blot. NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells. Cell , 2020, 182(3):685-712.e1 p53 database. p53 mutations in cell lines. The hanbook of p53 mutation in cell lines . Cell lines with a controversial p53 status . The NCI 60 panel. Bladder cancer cell lines . Brain cancer cell lines . Breast cancer cell lines . Cervical carcinoma. Colorectal cancer cell lines . Esophageal cancer cell lines. Gastric cancer cell lines . Head. p53 mutation is correlated with the high expression of GTSE1. GTSE1 mRNA expression level (Fig. 2a) and the GTSE1 protein level (Fig. 2b) was higher in the breast cancer tissues as compared to the normal breast tissues. Immunohistochemistry staining showed that GTSE1 was mainly located in the cytoplasm of breast cancer cells (Fig. 2c), and its protein expression level was higher in TNBC (Fig. Transfection of various p53 mutations into cells devoid of endogenous p53 leads to an increase in their carcinogenicity, which varies according to the type of mutation , , . Tumour Biol. A number of natural products have been found to alter expression either in the lab, with the particular natural product thought to work for different types of cancer
LFS p53 mutation carriers with the G-allele of MDM2 SNP309 and more cellular MDM2 were diagnosed with tumours on average 7 years earlier than those that were T/T in genotype. 6 This observation was reproduced in three independent studies, in which p53 mutation carriers with the G-allele were diagnosed with cancer on average 10, 16, and 12.5 years earlier. 7 The age of onset modifying effect of. p53 is the most commonly mutated tumor suppressor gene in human cancers. In addition to the loss of tumor suppression function and exertion of dominant-negative effects over the remaining wild-type protein, several p53 mutants can gain novel oncogenic functions (gain-of-function, GOF) that actively regulate cancer development and progression. In human endometrial cancer, p53 mutation is more. P53 (TP53) tumörprotein: funktion, mutation Tumörprotein 53, mer känt som p53 , är en proteinprodukt från en sträcka av deoxyribonukleinsyra (DNA) på kromosom 17 hos människor och på andra håll i andra eukaryota organismer
This mutation leads to an inability for the gene to block abnormal cellular growth . Some forms of the mutation produce a type of p53 protein that actually stimulates cell division and promotes the development of highly invasive cancers that are more apt to metastasize and more commonly fatal . Toxicity and p53 Gene Activit p53 Gene Therapy. A mutation in the p53 gene, which maintains normal cell function, can be found in many cancer cases. Gene therapy restores p53 and prevents cancer growth. Request a Free 2020 Mesothelioma Treatment Guid Lack of p53 nuclear accumulation was 86% (25/29) specific for absence of TP53 missense mutation. In FFPE prostate tumors, the positive predictive value of p53 nuclear accumulation for underlying missense mutation was 84% (38/45), whereas the negative predictive value was 97% (56/58)
. These included cells with R248Q, R248Q-TA, D281G and D281G-TA Analysis of the 107 tumours revealed mutation frequencies in p53 of 61%, APC of 56%, and K-ras of 27%, as previously reported. 18 These results are consistent with literature reports showing that APC was mutated in 50-83% of sporadic colorectal cancers, 22- 24 p53 was mutated in 41-69%, 3, 6, 25 and K-ras was mutated in 20-38%. 26- 29 Only 6% of tumours contained mutations in all. Mutation and abnormal expression of p53 was studied in 38 lymphomas [five Hodgkin's disease and 33 non-Hodgkin's lymphoma (NHL)]. CM1 polyclonal antibody was used to detect overexpression of p53. Three missense mutations were characterised in three cases of NHL after screening exons 5-8 of p53 of all the tumours with single-strand conformation polymorphism (SSCP) analysis
p53 tumor suppressor binds to DNA using all four of its arms. The mutations are found in and around the DNA-binding face of the protein. The most common mutation changes arginine 248, colored red here. Notice how it snakes into the minor groove of the DNA (shown in blue and green), forming a strong stabilizing interaction Several approaches have been adopted for detection of the p53 aberrations such as immunohistochemical analyses, immunoblotting, DNA sequencing, fluorescence in situ hybridization (FISH), and functional assays. We used these methods to characterize the p53 mutation in tumor cells of a 53-year-old male suffering from Burkitt's lymphoma Meta-analysis of p53 loss of function in NSCLC . Points; mean p53 activity as measured by transactivation with the WAF1promoter ; bars, 95 % CI.The mean and 95 % CI of p53 activity for all studies combined for a specific type of cancer is shown on the far left of each graph Dyskeratosis congenita is a cancer-prone inherited bone marrow failure syndrome caused by telomere dysfunction. A mouse model recently suggested that p53 regulates telomere metabolism, but the clinical relevance of this finding remained uncertain. Here, a germline missense mutation of MDM4 , a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita. . The frequency of germ line p53 mutations can now be examined in additional families with LFS, and in other cancer patients and families with clinical features that might be attributed to the mutation
Title:Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies VOLUME: 24 ISSUE: 30 Author(s):Raman Preet Kaur, Kanika Vasudeva, Roshan Kumar and Anjana Munshi* Affiliation:Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151001, Department of Human Genetics and Molecular Medicine, Central University of Punjab. Interestingly, Fn14 could exert anti-chemoresistance effect only in OVCAR-3 cells harboring a p53-R248Q mutation, but not in SKOV-3 cells with a p53-null mutation. We isolated and identified primary cells from two patients with the p53-R248Q mutation from HGSOC patients and the anti-chemoresistance effect of Fn14 was observed in both primary cells p53 (TP53) is a transcription factor whose protein levels and post-translational modification state alter in response to cellular stress (e.g. hypoxia, DNA and spindle damage). Activation of p53 occurs by several mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs . p53 Missense Mutation Library—2,314 p53 missense mutations were constructed recently through a 96-well, formatted, site-directed mutagenesis and stably expressed in a haploid yeast strain harboring a p53-responsive p21 WAF1 reporter plasmid (pAS03G) or in diploid yeast strains harboring p53-responsive reporter plasmids with a MDM2 promoter or p53 binding sequences derived from BAX (pKS07R.
OSTI.GOV Journal Article: p53 mutation heterogeneity in cancer. p53 mutation heterogeneity in cancer. Full Record; Other Related Researc A heterozygous point mutation of p53 gene at codon 280 from AGA to ACA (R280T) frequently occurs in nasopharyngeal carcinoma (NPC) cell lines, and about 10% NPC tissues. However, the role of this mutation in the pathogenesis of NPC remains unclear. In this study, we generated p53 knockout (KO) NPC cell lines from CNE2 cells carrying heterozygous p53 R280T (p53-R280T) mutation and C666-1 cells. p53 mutation remains the most common genetic change identified in human neoplasia. In breast cancer, p53 mutation is associated with more aggressive disease and worse overall survival. The frequency of mutation in p53 is, however, lower in breast cancer than in other solid tumours